Replimune prices $150 million stock offering at $12.06
Replimune Group (NASDAQ:REPL) priced an underwritten public offering of 9,701,490 shares at $12.06 per share, plus pre-funded warrants for 2,736,340 shares at $12.0599 per warrant, according to the company. Gross proceeds are expected at about $150 million. The offering is set to close Tuesday, subject to conditions.
How this was made
The 30-second read
Why it matters
The priced offering provides immediate gross funding but introduces dilution risk; traders may adjust expectations for balance-sheet runway and near-term share supply.
Market read
A newly priced equity offering is a direct, tradable catalyst for REPL due to dilution and capital-structure changes.
What to watch
Pre-funded warrants and the near-par pricing versus common stock can change effective dilution versus a standard warrant; closing timing and any concurrent buyback or guidance are not mentioned here.
Background
Replimune is a commercial-stage biotech developing oncolytic immunotherapies, with TUDRIQEV accelerated approval in combination with nivolumab for advanced melanoma.
Ticker impact
Replimune priced an underwritten public offering of 9,701,490 shares at $12.06 and expects about $150M gross proceeds.
Near-term downside or volatility risk around dilution expectations, with potential stabilization if investors view proceeds as runway for clinical/commercial execution.
The article discloses concrete offering size, price, and pre-funded warrants, which directly affect dilution and capital structure; it does not provide offsetting guidance or demand details.
Market effects
Biotech equity issuance signals continued reliance on capital markets, which can weigh on sentiment for cash-burner peers.
Limited, primarily affects US small/mid-cap biotech risk appetite.
Low; the event is company-specific and not a cross-market macro shock.
Counterpoint
If the offering price reflects strong demand and the company uses proceeds to de-risk late-stage programs, the market may quickly re-rate the funding risk.
Key entities
- companyReplimune Group, Inc.
NASDAQ-listed biotech that priced a $150M underwritten public stock offering and pre-funded warrants.
- productTUDRIQEV
Oncolytic immunotherapy referenced as having accelerated approval in combination with nivolumab.
- regulatorU.S. Securities and Exchange Commission
Shelf registration statement referenced (Form S-3 filed May 23, 2025, amended Nov 6, 2025).
